Monoid sublingual immunotherapy.
Sublingual monoid immunotherapy with monomeric allergoids has been largely used in Europe in the last few years. An open trial of allergoid in tablets has been done in rhinitic patients allergic to house dust mites, grass pollens and Parietaria with clear improvement in clinics and drug consumption scores. In a second phase a double blind placebo controlled trial of grass pollens allergoids have been done in hay fever patients with significant decrease on the scores of rhinorrea, sneezing and conjunctivitis nasal steroid consumption and clinical score after serial nasal challenges. Monomeric allergoids are an efficace and safe immunotherapy in allergic rhinitis.
Palma-Carlos
A G
AG
Clinical Allergy Immunology Center, CAIC, Lisbon, Portugal.
Santos
A S
AS
Branco-Ferreira
M
M
Pregal
A L
AL
Palma-Carlos
M L
ML
D000286:Administration, Sublingual; D000328:Adult; D000485:Allergens / Q000008:administration & dosage / Q000627:therapeutic use; D003233:Conjunctivitis, Allergic / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000379:methods*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D006109:Poaceae / Q000009:adverse effects; D011058:Pollen / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012221:Rhinitis, Allergic, Perennial / Q000628:therapy*; D006255:Rhinitis, Allergic, Seasonal / Q000628:therapy*; D013607:Tablets; D016896:Treatment Outcome
D000485:Allergens; D013607:Tablets